Anzeige
Meldung des Tages: Strom schlägt Bitcoin – Die eigentliche Schlacht im Bitcoin-Markt wird auf der Stromrechnung entschieden

Oncolytics Biotech News

Aktie
WKN:  A2JMW5 ISIN:  CA6823108759 Branche:  Biotechnologie Land:  Kanada
0,9403 $
+0,0854 $
+9,99%
0,8028 € 01.04.26
Depot/Watchlist
Marktkapitalisierung *
62,33 Mio. €
Streubesitz
94,71%
KGV
-3,21
Index-Zuordnung
Nasdaq Composite Index

Oncolytics Biotech News

05.08.25 - PR Newswire
Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results PR Newswire
29.07.25 - PR Newswire
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
Biotech Underdogs Line Up for Pivotal Shots at Game-​Changing Cancer Treatments PR Newswire
29.07.25 - PR Newswire
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
Biotech Underdogs Line Up for Pivotal Shots at Game-​Changing Cancer Treatments PR Newswire
29.07.25 - PR Newswire
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
Oncolytics Biotech® to Engage FDA for Potential Registration-​Enabled Study in First-​Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End PR Newswire
23.07.25 - PR Newswire
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential PR Newswire
23.07.25 - PR Newswire
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds PR Newswire
23.07.25 - PR Newswire
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds PR Newswire
22.07.25 - PR Newswire
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules PR Newswire
16.07.25 - PR Newswire
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities PR Newswire
16.07.25 - PR Newswire
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities PR Newswire
16.07.25 - PR Newswire
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types PR Newswire
10.07.25 - PR Newswire
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up PR Newswire
10.07.25 - PR Newswire
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up PR Newswire
10.07.25 - PR Newswire
Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers
Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers PR Newswire
08.07.25 - PR Newswire
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention PR Newswire
08.07.25 - PR Newswire
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention PR Newswire
08.07.25 - PR Newswire
Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-​Enabling Studies PR Newswire
30.06.25 - PR Newswire
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch PR Newswire
30.06.25 - PR Newswire
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch PR Newswire
30.06.25 - PR Newswire
Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy PR Newswire

Newssuche

Videos

newspaper
20.04.26 +0,17%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »